Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune Activity

By E. Suzuki, V. Kapoor, A. Jassar, L. Kaiser, S. Albelda. Clinical Cancer Research, 2005

1,061 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/ad45d393abcdb4b919f72fd99160237b2eaca5fb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

Citations in the corpus

Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. (2007, background): “They mediate their effects by inhibiting CD4 and CD8 T cell proliferation (6–10), by blocking natural killer cell activation (11, 12), by limiting dendritic cell maturation (13), and by polarizing immunity towards a type 2 phenotype (14).”
The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies (2015, background): “In addition, gemcitabine significantly reduced MDSCs in preclinical animal models (24, 26, 27).”
T Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis (2012, background): “When given at a clinically equivalent dose, gemcitabine resulted in a dramatically reduced number ofMDSCs in animal spleens, accompanied by an increase in the antitumor activity of CD8þ T cells and activated NK cells (64).”
Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer (2009, background): “Several studies have demonstrated that MDSC inhibit NK cell cytotoxicity against tumor cells and block NK production of IFN- and that these activities require cell contact between the MDSC and target cells (60, 63, 69).”
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy (2008, background): “In the context of MDSC this is particularly relevant because chemotherapy, e.g. gemcitabine and bevacizumab, may decrease the proportion of MDSC present in PBMCs [2, 28].”
Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. (2015, background): “…used commonly used for the treatment of pancreatic carcinoma, reduces the amount of circulating MDSCs, favors the reprogramming of TAMs toward an immunostimulatory phenotype, and boosts cross-priming, at least in murine tumor models (Di Caro et al., 2015; Nowak et al., 2003; Suzuki et al., 2005).”
Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. (2013, background): “Gemcitabine, a nucleosideanalog, specifically reduces splenic MDSCs (Gr-1+/CD11b+ cells) in tumor-bearing mice, while leaving the effector functions of local NK cells unaffected (Suzuki et al., 2005).”
Proinflammatory S100 Proteins Regulate the Accumulation of Myeloid-Derived Suppressor Cells (2008, background): “Since MDSC are a significant impediment to active T and NK cell immunotherapies (65), targeting of S100A8/A9 binding may improve immunotherapy with cancer vaccines and other immune strategies that require an immune-competent host.”